| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
| ln Vitro |
TUNEL labeling of free 3'-OH DNA ends demonstrated that cyclophosphamide promotes outer membrane blebbing, leading to DNA fragmentation, and promoting cleavage of the caspase 3 and caspase 7 substrate PARP in 9L/P450 cells. Bcl-2 expression totally prevents activation of initiator and effector caspase 3 in cells treated with activated cyclophosphamide. Bcl-2 suppresses the cytotoxic effects but not the cytostatic effects of activated cyclophosphamide [1]. Cyclophosphamide reversibly inhibits AChE with an IC50 of 511 μM [2]. Carbon tetrachloride does not impact the direct cytotoxicity of cyclophosphamide or 4-hydroxycyclophosphamide to cultivated cells [3].
|
|---|---|
| ln Vivo |
Cyclophosphamide increases the percentage of cells stained for CD3, CD4, or CD8 in the spleen and tumors when given intraperitoneally (i.p.) to SW1 tumor-bearing C3H mice (2 mg/mouse in 0.1 mL PBS) [4].
|
| Animal Protocol |
Animal/Disease Models: Six- to eightweeks old female C3H/HeN mice bearing SW1 tumors [4]
Doses: 2 mg/mouse Route of Administration: intraperitoneal (ip) injection; 2 mg/mouse in 0.1 mL PBS; Four-day Experimental Results: spleen and an increase in the percentage of cells staining for CD3, CD4, or CD8 in the tumor. |
| References |
[1]. Schwartz PS, et al. Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. Mol Pharmacol. 2001 Dec;60(6):1268-1279.
[2]. Liu P, et al. Administration of cyclophosphamide changes the immune profile of tumor-bearing mice. J Immunother. 2010 Jan;33(1):53-9. [3]. al-Jafari AA, et al. Inhibition of human acetylcholinesterase by cyclophosphamide. Toxicology. 1995 Jan 19;96(1):1-6. [4]. Harris RN, et al. Carbon tetrachloride-induced increase in the antitumor activity of cyclophosphamide in mice: a pharmacokineticstudy. Cancer Chemother Pharmacol. 1984;12(3):167-72. |
| Molecular Formula |
C7H17CL2N2O3P
|
|---|---|
| Molecular Weight |
279.1012
|
| CAS # |
6055-19-2
|
| Related CAS # |
Cyclophosphamide;50-18-0;Cyclophosphamide-d8 hydrate
|
| SMILES |
ClC([H])([H])C([H])([H])N(C([H])([H])C([H])([H])Cl)P1(N([H])C([H])([H])C([H])([H])C([H])([H])O1)=O.O([H])[H]
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product is not stable in solution, please use freshly prepared working solution for optimal results. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 50 mg/mL (~179.15 mM)
DMSO : ≥ 38 mg/mL (~136.15 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.96 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.96 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.96 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 25 mg/mL (89.57 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5829 mL | 17.9147 mL | 35.8295 mL | |
| 5 mM | 0.7166 mL | 3.5829 mL | 7.1659 mL | |
| 10 mM | 0.3583 mL | 1.7915 mL | 3.5829 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
